Drug Safety

, Volume 26, Issue 11, pp 743–747 | Cite as

Tolcapone-Related Liver Dysfunction

Implications for Use in Parkinson’s Disease Therapy
Practical Drug Safety


Levodopa is the cornerstone of idiopathic Parkinson’s disease (PD) treatment. However, after long-term use of levodopa, a significant percentage of patients experience motor fluctuations, which worsen their quality of life. Catechol-O-methyltransferase (COMT) inhibitors reduce levodopa metabolism and enhance the respective plasma levels, resulting in improvements in symptoms and overall quality of life.

Tolcapone was the first drug of this class to be marketed, but was withdrawn in the European Union due to its implication in the deaths of three PD patients due to hepatic failure. Three deaths from fulminant hepatic failure in 40 000 patient-years is a number that is 10–100 times higher than the expected incidence in the general population and, according to the manufacturer’s own information, the number is probably underestimated due to under-reporting of cases.

In the US, tolcapone was not withdrawn, but restrictive liver enzyme monitoring measures were issued by authorities, which severely limited its use. No further deaths from hepatic failure were reported since these measures were implemented.

The mechanisms by which tolcapone may induce liver toxicity are still under debate. It was thought that mitochondrial uncoupling of oxidative phosphorylation by tolcapone, and consequent impairment of energy production by hepatocytes, could be responsible for the observed effects.

Some experts consider that the restrictive guidelines issued in the US regarding tolcapone use may be loosened with no consequential reductions in safety. It was suggested that ongoing clinical information about safety should be considered and periodical revisions of the restrictions made accordingly. The identification of the molecular and biochemical basis of tolcapone hepatotoxicity, when completed, should also provide important indications for the clinical use of this drug.

In conclusion, appropriate monitoring of liver function can ensure adequate safety in PD patients receiving tolcapone, who can therefore benefit from the symptomatic improvements obtained with this drug.


Levodopa Liver Toxicity Fulminant Hepatic Failure Entacapone Motor Fluctuation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors received no funding to assist in the preparation of this manuscript. The authors have provided no information on conflicts of interest directly relevant to the content of this review.


  1. 1.
    Ruottinen HM, Rinne UK. COMT inhibition in the treatment of Parkinson’s disease. J Neurol 1998; 245(11 Suppl. 3): 25–34CrossRefGoogle Scholar
  2. 2.
    Borges N, Vieira-Coelho MA, Parada A, et al. Studies on the tight-binding nature of tolcapone inhibition of soluble and membrane-bound rat brain catechol-O-methyltransferase. J Pharmacol Exp Ther 1997; 282(2): 812–7PubMedGoogle Scholar
  3. 3.
    Zurcher G, Keller HH, Kettler R, et al. Ro 40-7592, a novel, very potent, and orally active inhibitor of catechol-O-methyltransferase: a pharmacological study in rats. Adv Neurol 1990; 53: 497–503PubMedGoogle Scholar
  4. 4.
    Zurcher G, Colzi A, Da Prada M. Ro 40-7592: inhibition of COMT in rat brain and extracerebral tissues. J Neural Transm Suppl 1990; 32: 375–80PubMedGoogle Scholar
  5. 5.
    Mannisto PT, Ulmanen I, Lundstrom K, et al. Characteristics of catechol O-methyl-transferase (COMT) and properties of selective COMT inhibitors. Prog Drug Res 1992; 39: 291–350PubMedGoogle Scholar
  6. 6.
    Nutt JG, Fellman JH. Pharmacokinetics of levodopa. Clin Neuropharmacol 1984; 7(1): 35–49PubMedCrossRefGoogle Scholar
  7. 7.
    Gomes P, Soares-da-Silva P. Interaction between L-DOPA and 3-O-methyl-L-DOPA for transport in immortalised rat capillary cerebral endothelial cells. Neuropharmacology 1999; 38(9): 1371–80PubMedCrossRefGoogle Scholar
  8. 8.
    Reches A, Mielke LR, Fahn S. 3-o-methyldopa inhibits rotations induced by levodopa in rats after unilateral destruction of the nigrostriatal pathway. Neurology 1982; 32(8): 887–8PubMedCrossRefGoogle Scholar
  9. 9.
    Dupont E, Burgunder JM, Findley LJ, et al. Tolcapone added to levodopa in stable parkinsonian patients: a double-blind placebo-controlled study. Tolcapone in Parkinson’s Disease Study Group II (TIPS II). Mov Disord 1997; 12(6): 928–34PubMedCrossRefGoogle Scholar
  10. 10.
    Roberts JW, Cora-Locatelli G, Bravi D, et al. Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. Neurology 1993; 43(12): 2685–8PubMedCrossRefGoogle Scholar
  11. 11.
    Spencer CM, Benfield P. Tolcapone. CNS Drugs 1996; 5(6): 475–81CrossRefGoogle Scholar
  12. 12.
    Waters CH, Kurth M, Bailey P, et al. Tolcapone in stable Parkinson’s disease: efficacy and safety of long-term treatment. The Tolcapone Stable Study Group. Neurology 1997; 49(3): 665–71PubMedCrossRefGoogle Scholar
  13. 13.
    Watkins P. COMT inhibitors and liver toxicity. Neurology 2000; 55(11 Suppl. 4): S51–2PubMedGoogle Scholar
  14. 14.
    Kurth MC, Adler CH, Hilaire MS, et al. Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. Neurology 1997; 48(1): 81–7PubMedCrossRefGoogle Scholar
  15. 15.
    Assal F, Spahr L, Hadengue A, et al. Tolcapone and fulminant hepatitis [letter]. Lancet 1998; 352(9132): 958PubMedCrossRefGoogle Scholar
  16. 16.
    Colosimo C. The rise and fall of tolcapone. J Neurol 1999; 246(10): 880–2PubMedCrossRefGoogle Scholar
  17. 17.
    European Medicine Evaluation Agency. Recommendation for the suspension of the marketing authorization for Tasmar (tolcapone) [press release]. London: EMEA, 1998Google Scholar
  18. 18.
    Ellison RH. Dear Healthcare Professional letter regarding appropriate use of Tasmar. Nutley (NJ): Roche Laboratories Inc, 1998 Nov 16Google Scholar
  19. 19.
    Roche Laboratories. Tasmar® (tolcapone tablets) prescribing information. Nutley (NJ): 1998Google Scholar
  20. 20.
    Spahr L, Rubbia-Brandt L, Burkhard PR, et al. Tolcapone-related fulminant hepatitis: electron microscopy shows mitochondrial alterations. Dig Dis Sci 2000; 45(9): 1881–4PubMedCrossRefGoogle Scholar
  21. 21.
    Nissinen E, Kaheinen P, Penttila KE, et al. Entacapone, a novel catechol-O-methyltransferase inhibitor for Parkinson’s disease, does not impair mitochondrial energy production. Eur J Pharmacol 1997; 340(2-3): 287–94PubMedCrossRefGoogle Scholar
  22. 22.
    Haasio K, Sopanen L, Vaalavirta L, et al. Comparative toxicological study on the hepatic safety of entacapone and tolcapone in the rat. J Neural Transm 2001; 108(1): 79–91PubMedCrossRefGoogle Scholar
  23. 23.
    Lautala P, Ethell BT, Taskinen J, et al. The specificity of glucuronidation of entacapone and tolcapone by recombinant human UDP-glucuronosyltransferases. Drug Metab Dispos 2000; 28(11): 1385–9PubMedGoogle Scholar
  24. 24.
    New warnings for Parkinson’s drug, Tasmar. T98-81. 16-11-1998. Rockville (MD): Food and Drug Administration. Talk PaperGoogle Scholar
  25. 25.
    Olanow CW. Tolcapone and hepatotoxic effects. Tasmar Advisory Panel. Arch Neurol 2000; 57(2): 263–7PubMedCrossRefGoogle Scholar
  26. 26.
    Kaakkola S. Clinical pharmacology, therapeutic use and potential of COMT inhibitors in Parkinson’s disease. Drugs 2000; 59(6): 1233–50PubMedCrossRefGoogle Scholar
  27. 27.
    Factor SA, Molho ES, Feustel PJ, et al. Long-term comparative experience with tolcapone and entacapone in advanced Parkinson’s disease. Clin Neuropharmacol 2001; 24(5): 295–9PubMedCrossRefGoogle Scholar
  28. 28.
    Onofrj M, Thomas A, Iacono D, et al. Switch-over from tolcapone to entacapone in severe Parkinson’s disease patients. Eur Neurol 2001; 46(1): 11–6PubMedCrossRefGoogle Scholar
  29. 29.
    Shepherd J, Clegg A. Entacapone as an adjunctive treatment to levodopa in Parkinson’s disease. Southampton, Wessex Institute for Health Research and Development. 1999. Development and Evaluation Committee Report No. 104Google Scholar
  30. 30.
    Rinne UK, Larsen JP, Siden A, et al. Entacapone enhances the response to levodopa in parkinsonian patients with motor fluctuations. Nomecomt Study Group. Neurology 1998; 51(5): 1309–14PubMedCrossRefGoogle Scholar
  31. 31.
    Entacapone improves motor fluctuations in levodopa-treated Parkinson’s disease patients. Parkinson Study Group. Ann Neurol 1997; 42 (5): 747–55Google Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  1. 1.Faculdade de Ciências da Nutrição e Alimentação da Universidade do PortoPortoPortugal

Personalised recommendations